#1 Clinical Trials Search in Europe

Study on the Safety of LY3884961 for Patients with Type 1 Gaucher Disease

1 1 1 1

What is this study about?

This clinical trial is focused on studying Type 1 Gaucher Disease, which is a condition that affects certain parts of the body but not the brain. The study will test a new treatment called LY3884961, which is given as a single dose through an intravenous infusion, meaning it is delivered directly into the bloodstream. The main goal of the study is to see how safe and tolerable this treatment is for patients with this type of Gaucher Disease.

During the study, participants will receive a single dose of LY3884961 and will be monitored for any side effects or changes in their health. This includes regular checks of vital signs, blood tests, and imaging tests like MRIs to look at the abdomen and bones. The study will also track changes in certain proteins and antibodies in the blood, which can help understand how the body is responding to the treatment.

The study will take place over several years, with participants being followed up regularly to monitor their health and any long-term effects of the treatment. The researchers will also look at how the treatment affects the size of the spleen, the number of platelets in the blood, and the activity of certain enzymes related to Gaucher Disease. This information will help determine if LY3884961 could be a beneficial treatment option for people with Type 1 Gaucher Disease.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying age, genetic mutations, and current treatment stability.

Participants must have been on enzyme replacement therapy (ERT) or substrate reduction therapy (SRT) for at least two years and on a stable dose for at least three months.

2 consent and preparation

Participants provide informed consent, agreeing to comply with study requirements and restrictions.

Participants must agree to use effective contraception and abstain from blood donations for the first year.

3 medication administration

A single intravenous dose of LY3884961 is administered to evaluate safety and tolerability.

This medication is delivered through an intravenous infusion.

4 monitoring and follow-up

Participants are monitored for any adverse effects, including changes in vital signs, laboratory parameters, and physical examinations.

Regular assessments include 12-lead ECGs, abdominal and bone MRIs, and measurements of waist circumference and weight.

5 evaluation of treatment effects

The study evaluates changes in complement proteins and the presence of specific antibodies.

Changes in spleen volume, platelet count, and enzyme activity are also assessed.

6 long-term follow-up

Participants are followed up to determine the time from LY3884961 administration to discontinuation of ERT/SRT.

The study also monitors the time from discontinuation to potential re-initiation of ERT/SRT.

Who Can Join the Study?

  • Must be between the ages of 18 and 65 at the time of giving consent to participate.
  • Must have two copies of a specific gene change called GBA1 mutations, which will be confirmed by the study team.
  • Must have been receiving treatment called ERT (Enzyme Replacement Therapy) or SRT (Substrate Reduction Therapy) for at least 2 years and be on a stable dose for at least 3 months before the study starts.
  • Must be able to understand and sign a document that explains the study and agree to follow the study rules.
  • Both females and males can participate. Those who can have children must use a very effective method to prevent pregnancy during the study and follow-up period.
  • Must agree not to donate blood for at least the first year of the study.

Who Cannot Join the Study?

  • Patients with any other serious health condition that might interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have participated in another clinical trial recently.
  • Patients who have a history of allergic reactions to similar treatments.
  • Patients who are unable to follow the study procedures or instructions.
  • Patients with a history of drug or alcohol abuse.
  • Patients who have received certain medications that might affect the study results.
  • Patients with any condition that the study doctors believe would make participation unsafe.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name City Country Status
SphinCS GmbH Hochheim Am Main Germany
Hospital Quironsalud Zaragoza Zaragoza Spain

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
Germany Germany
Not yet recruiting
02.10.2023
Spain Spain
Not yet recruiting
02.10.2023

Trial locations

Investigated drugs:

LY3884961 is an investigational medication being studied for its potential to treat Gaucher Disease, which is a condition that affects various parts of the body. This medication is given as a single dose through an intravenous infusion, meaning it is administered directly into the bloodstream. The main goal of the study is to assess how safe and tolerable this medication is for patients who have symptoms of Gaucher Disease affecting areas outside the central nervous system.

Investigated diseases:

Type 1 Gaucher Disease – This is a genetic disorder caused by a deficiency in the enzyme glucocerebrosidase, leading to the accumulation of fatty substances in certain organs, particularly the spleen and liver. It is characterized by symptoms such as enlarged liver and spleen, low blood platelet counts, and bone abnormalities. The disease does not affect the nervous system, distinguishing it from other types of Gaucher disease. Over time, individuals may experience fatigue, bleeding, and bone pain or fractures. The progression of the disease can vary widely among individuals, with some experiencing mild symptoms and others more severe complications.

Trial ID:
2022-500281-10-02
Protocol code:
J3Z-MC-OJAE
NCT ID:
NCT05487599
Trial Phase:
Human Pharmacology (Phase I) – Other

Other Trials to Consider

  • Study of Eliglustat alone or with Imiglucerase in children and adolescents aged 2-17 years with Gaucher disease type 1 and type 3

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study on the Long-term Safety of FLT201 for Patients with Gaucher Disease Type 1

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain